Quest Diagnostics Free Cash Flow (FCF) History (DGX)
Quest Diagnostics reported $1.36B in free cash flow for fiscal 2025, an increase of 49.50% from the previous fiscal year, with a free cash flow margin of 12.32%.
View full Quest Diagnostics company overviewQuest Diagnostics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.36B | $450.0M | +49.50% | +12.32% |
| 2024 | 2024-12-31 | $909.0M | $45.0M | +5.21% | +9.21% |
| 2023 | 2023-12-31 | $864.0M | −$450.0M | −34.25% | +9.34% |
| 2022 | 2022-12-31 | $1.31B | −$516.0M | −28.20% | +13.30% |
| 2021 | 2021-12-31 | $1.83B | $243.0M | +15.31% | +16.96% |
| 2020 | 2020-12-31 | $1.59B | $744.0M | +88.26% | +16.82% |
| 2019 | 2019-12-31 | $843.0M | $26.0M | +3.18% | +10.91% |
| 2018 | 2018-12-31 | $817.0M | −$106.0M | −11.48% | +10.85% |
| 2017 | 2017-12-31 | $923.0M | $100.0M | +12.15% | +12.47% |
| 2016 | 2016-12-31 | $823.0M | $265.0M | +47.49% | +11.41% |
| 2015 | 2015-12-31 | $558.0M | −$78.0M | −12.26% | +7.45% |
| 2014 | 2014-12-31 | $636.0M | $215.0M | +51.07% | +8.55% |
| 2013 | 2013-12-31 | $421.0M | −$584.0M | −58.11% | +5.89% |
| 2012 | 2012-12-31 | $1.00B | $271.0M | +36.92% | +13.61% |
| 2011 | 2011-12-31 | $734.0M | −$178.6M | −19.57% | +9.93% |
| 2010 | 2010-12-31 | $912.6M | $82.2M | +9.89% | +12.57% |
| 2009 | 2009-12-31 | $830.5M | −$19.9M | −2.34% | +11.14% |
| 2008 | 2008-12-31 | $850.4M | $142.5M | +20.14% | +11.73% |
| 2007 | 2007-12-31 | $707.8M | — | — | +10.56% |
Quest Diagnostics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $459.0M | $23.0M | +5.28% | +15.08% |
| Q1 2026 | 2026-03-31 | $164.0M | −$33.0M | −16.75% | +5.66% |
| Q4 2025 | 2025-12-31 | $307.0M | −$34.0M | −9.97% | +10.94% |
| Q3 2025 | 2025-09-30 | $419.0M | $169.0M | +67.60% | +14.88% |
| Q2 2025 | 2025-06-30 | $436.0M | $168.0M | +62.69% | +15.79% |
| Q1 2025 | 2025-03-31 | $197.0M | $147.0M | +294.00% | +7.43% |
| Q4 2024 | 2024-12-31 | $341.0M | −$114.0M | −25.05% | +13.01% |
| Q3 2024 | 2024-09-30 | $250.0M | $148.0M | +145.10% | +10.05% |
| Q2 2024 | 2024-06-30 | $268.0M | −$72.0M | −21.18% | +11.18% |
| Q1 2024 | 2024-03-31 | $50.0M | $83.0M | — | +2.11% |
| Q4 2023 | 2023-12-31 | $455.0M | $268.0M | +143.32% | +19.89% |
| Q3 2023 | 2023-09-30 | $102.0M | −$282.0M | −73.44% | +4.44% |
| Q2 2023 | 2023-06-30 | $340.0M | $14.0M | +4.29% | +14.54% |
| Q1 2023 | 2023-03-31 | −$33.0M | −$450.0M | — | −1.42% |
| Q4 2022 | 2022-12-31 | $187.0M | −$150.0M | −44.51% | +8.02% |
| Q3 2022 | 2022-09-30 | $384.0M | −$88.0M | −18.64% | +15.45% |
| Q2 2022 | 2022-06-30 | $326.0M | −$50.0M | −13.30% | +13.29% |
| Q1 2022 | 2022-03-31 | $417.0M | −$228.0M | −35.35% | +15.97% |
| Q4 2021 | 2021-12-31 | $337.0M | −$42.0M | −11.08% | +12.28% |
| Q3 2021 | 2021-09-30 | $472.0M | −$299.0M | −38.78% | +17.02% |
| Q2 2021 | 2021-06-30 | $376.0M | $103.0M | +37.73% | +14.75% |
| Q1 2021 | 2021-03-31 | $645.0M | $481.0M | +293.29% | +23.71% |
| Q4 2020 | 2020-12-31 | $379.0M | $203.0M | +115.34% | +12.62% |
| Q3 2020 | 2020-09-30 | $771.0M | $568.0M | +279.80% | +27.67% |
| Q2 2020 | 2020-06-30 | $273.0M | $37.0M | +15.68% | +14.94% |
| Q1 2020 | 2020-03-31 | $164.0M | −$64.0M | −28.07% | +9.00% |
| Q4 2019 | 2019-12-31 | $176.0M | $32.0M | +22.22% | +9.14% |
| Q3 2019 | 2019-09-30 | $203.0M | −$118.0M | −36.76% | +10.38% |
| Q2 2019 | 2019-06-30 | $236.0M | −$9.0M | −3.67% | +12.08% |
| Q1 2019 | 2019-03-31 | $228.0M | $121.0M | +113.08% | +12.06% |
| Q4 2018 | 2018-12-31 | $144.0M | −$97.0M | −40.25% | +7.83% |
| Q3 2018 | 2018-09-30 | $321.0M | $22.0M | +7.36% | +16.99% |
| Q2 2018 | 2018-06-30 | $245.0M | $16.0M | +6.99% | +12.77% |
| Q1 2018 | 2018-03-31 | $107.0M | −$47.0M | −30.52% | +5.68% |
| Q4 2017 | 2017-12-31 | $241.0M | $18.0M | +8.07% | +12.92% |
| Q3 2017 | 2017-09-30 | $299.0M | $59.0M | +24.58% | +16.11% |
| Q2 2017 | 2017-06-30 | $229.0M | −$25.0M | −9.84% | +12.29% |
| Q1 2017 | 2017-03-31 | $154.0M | $48.0M | +45.28% | +8.48% |
| Q4 2016 | 2016-12-31 | $223.0M | $45.0M | +25.28% | +14.29% |
| Q3 2016 | 2016-09-30 | $240.0M | $80.0M | +50.00% | +12.73% |
| Q2 2016 | 2016-06-30 | $254.0M | $30.0M | +13.39% | +13.33% |
| Q1 2016 | 2016-03-31 | $106.0M | $110.0M | — | +5.69% |
| Q4 2015 | 2015-12-31 | $178.0M | −$42.0M | −19.09% | +9.63% |
| Q3 2015 | 2015-09-30 | $160.0M | −$9.0M | −5.33% | +8.51% |
| Q2 2015 | 2015-06-30 | $224.0M | −$7.0M | −3.03% | +11.64% |
| Q1 2015 | 2015-03-31 | −$4.0M | −$20.0M | — | −0.22% |
| Q4 2014 | 2014-12-31 | $220.0M | $86.0M | +64.18% | +11.68% |
| Q3 2014 | 2014-09-30 | $169.0M | $32.0M | +23.36% | +8.88% |
| Q2 2014 | 2014-06-30 | $231.0M | $79.0M | +51.97% | +12.15% |
| Q1 2014 | 2014-03-31 | $16.0M | $18.0M | — | +0.92% |
| Q4 2013 | 2013-12-31 | $134.0M | −$186.6M | −58.20% | +7.63% |
| Q3 2013 | 2013-09-30 | $137.0M | −$212.7M | −60.82% | +7.66% |
| Q2 2013 | 2013-06-30 | $152.0M | −$51.5M | −25.29% | +8.37% |
| Q1 2013 | 2013-03-31 | −$2.0M | −$133.3M | — | −0.11% |
| Q4 2012 | 2012-12-31 | $320.6M | $26.4M | +8.98% | +18.07% |
| Q3 2012 | 2012-09-30 | $349.7M | $51.3M | +17.20% | +19.20% |
| Q2 2012 | 2012-06-30 | $203.5M | $183.6M | +923.94% | +10.83% |
| Q1 2012 | 2012-03-31 | $131.3M | $9.7M | +7.96% | +6.88% |
| Q4 2011 | 2011-12-31 | $294.2M | $23.7M | +8.75% | +16.71% |
| Q3 2011 | 2011-09-30 | $298.4M | $15.8M | +5.58% | +15.65% |
| Q2 2011 | 2011-06-30 | $19.9M | −$140.2M | −87.59% | +1.04% |
| Q1 2011 | 2011-03-31 | $121.6M | −$77.9M | −39.04% | +6.67% |
| Q4 2010 | 2010-12-31 | $270.5M | −$39.9M | −12.87% | +15.77% |
| Q3 2010 | 2010-09-30 | $282.6M | −$49.9M | −15.00% | +15.16% |
| Q2 2010 | 2010-06-30 | $160.1M | $205.7M | — | +8.54% |
| Q1 2010 | 2010-03-31 | $199.5M | −$33.7M | −14.45% | +11.05% |
| Q4 2009 | 2009-12-31 | $310.4M | — | — | +16.80% |
| Q3 2009 | 2009-09-30 | $332.5M | — | — | +17.53% |
| Q2 2009 | 2009-06-30 | −$45.6M | — | — | −2.40% |
| Q1 2009 | 2009-03-31 | $233.2M | — | — | +12.90% |
Quest Diagnostics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $1.59B to $1.36B, a compound annual decline of 3.05%. Quest Diagnostics's latest reported quarter, Q2 2026, generated $459.0M in free cash flow, an increase of 5.28% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Quest Diagnostics filings at SEC.gov ↗